Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Steroid shot may buy time for men with tough prostate cancer

NCT ID NCT07161778

Disease control Sponsor: Barts & The London NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tested a steroid injection called triamcinolone in 55 men with castration resistant prostate cancer, a type that no longer responds to standard hormone therapy. The goal was to see if it could extend the time before chemotherapy is needed, since current steroid treatments only work about 4 months on average. Researchers believe triamcinolone may work differently and avoid resistance seen with other steroids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
triamcinolone injection
What this could lead to
If it works, this could offer a longer period of disease control before chemotherapy is needed, improving quality of life for older men.
What could go wrong
This is a small, early-phase trial with only 55 participants and no comparison group, so results may not be conclusive. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

55 people

The number who actually took part.

Started

Oct 2011

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the prostate 2. Progressive disease despite castration with an elevated PSA \>5ng/ml (testosterone \<1.5nmol/l or failure of GnRH analogue with peripheral anti-androgen if non-castrate level on GnRH alone) 3. ECOG performance status (PS) 0-3 and considered by responsible consultant suitable to undergo treatment 4. Males aged greater or equal than 18 5. Patients who are able to understand their participation in the study and give written informed consent Exclusion Criteria: 1. Contraindication to intramuscular injections 2. Unable to titrate medication for type 2 diabetes if deterioration in control on triamcinolone 3. Absolute contraindication to corticosteroids 4. Previous use of corticosteroids in prostate cancer 5. Previous chemotherapy for prostate cancer 6. Current participation in any other investigational drug study 7. History of a malignancy within 5 years except those treated with curative intent for skin cancer (other than melanoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Castration-resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Castration-resistant prostate cancer

Contacts and locations

Locations

  • Raigmore Hospital

    Inverness, United Kingdom

  • Royal Sussex County Hospital

    Brighton, United Kingdom

  • St Bartholomew's Hospital

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.